
Survival Outcomes Linked to Timing of Immune Checkpoint Inhibitor Dosing
A new analysis from a large, single-centre cohort suggests that when immune checkpoint inhibitors are given can meaningfully shape outcomes for patients with advanced cancer. The study, reported in British Journal of Cancer,







